The International Journal of Frontier Sciences

(ISSN: 2618-0367) Open Access Journal
Rss Feed:

Special Issue CRISPR and Gene Editing in Disease Treatment: From Bench to Bedside » details

A special issue of Int J Front Sci (ISSN 2618-0367).

Deadline for manuscript submissions: closed (31 August 2020)

Special Issue Information

Gene editing has moved rapidly from a powerful laboratory concept to a serious clinical platform with the potential to transform disease treatment.  CRISPR-Cas systems and newer tools such as base and prime editing are reshaping how researchers approach pathogenic mutations, immune engineering, and targeted therapeutic development.

This special issue will explore the current state of the art in CRISPR and gene editing, with particular attention to the translational path from experimental innovation to real-world clinical application. We welcome contributions addressing both the promise and the practical challenges of using gene editing to treat monogenic, complex, infectious, inflammatory, and malignant diseases.

Areas of interest include, but are not limited to:

  • next-generation editing technologies
  •  AI-assisted guide RNA design and off-target prediction
  • CRISPR applications in oncology, CAR-T engineering, and hematologic disorders
  • gene editing in infectious and autoimmune disease
  • delivery systems including viral and non-viral platforms

We encourage original research articles, systematic reviews, meta-analyses, and perspectives that provide clinically relevant insights and advance evidence-based interdisciplinary practice.

TIJFS is globally distributed through its online, open-access platform, allowing unrestricted access to readers worldwide. Please follow instructions for authors to submit to this special issue. Authors must choose this special issue at time of submission to be considered in this special issue. We look forward to your contribution. APCs information can be accessed here. Additional waivers or discounts can be granted to authors with special circumstances.

For any questions, feel free to reach out editorial office at editor@tijfs.org.

Review
Int J Front Sci 2026, 8(2), 7; doi: 10.37978/tijfs.v08i02.007
Received: 20 Aug 2026 / Accepted: 21 Oct 2026 / Published: 13 Nov 2026
Background: As the world witnesses remarkable advances in targeted drug and gene delivery, we see the emergence of two important nanocarrier-based systems for accurate destination locking, lipid nanoparticles (LNPs) and polymersomes, with the promise of providing precision, efficiency and accuracy in therapeutic drug
[...] Read more.
Background: As the world witnesses remarkable advances in targeted drug and gene delivery, we see the emergence of two important nanocarrier-based systems for accurate destination locking, lipid nanoparticles (LNPs) and polymersomes, with the promise of providing precision, efficiency and accuracy in therapeutic drug load transport. With sufficient tunability, impressive physicochemical properties and the potential for controlled release, both these systems appear to be a great solution to problems like biodistribution and lability. Despite the advanced research and their clinical utility, challenges remain in achieving site-specific targeting, large-scale reproducibility, and long-term safety. Methods: A detailed literature review was conducted to study the detailed differences in mechanism, types and effectivity of various polymeric and lipid-based nanoparticles for targeted drug delivery by reviewing the published peer-reviewed articles from recent years. Results: This review combines current developments in engineering strategies for functionalization, stimuli responsiveness, and hybrid design of LNPs and polymersomes while comparing the advantages, hurdles and regulatory considerations. Finally, emerging directions in precision nanomedicine such as bioinspired nanocarriers, AI-assisted formulation design, and multifunctional theranostic systems are discussed as pathways toward more effective, targeted and personalized therapies. Conclusions: The literature study suggests that only LNPs have been approved for clinical applications whereas polymersomes are in a translational pipeline. However, both LNPs and polymeric nanoparticles have their own significance and uses in biological applications, in enhancing biocompatibility and bioavailability of both hydrophobic and hydrophilic drugs. Full article